Tom Mirga
Editor at Large
The 340B program “is a really successful program and it hasn’t really cut the profits of the pharmaceutical companies dramatically,” U.S. Senate Majority Whip Dick Durbin (D-Ill.) said Friday during a visit to a Chicago-based community health center.
Durbin is
…
Laura Gilcrest
Editor at Large
Pharmaceutical Research and Manufacturers of America asked a U.S. appeals court in St. Louis, Mo. last week to strike down Arkansas’s first-of-its-kind 340B contract pharmacy law, arguing that it intrudes on the 340B statute and frustrates Congress’ intent to limit
… Tom Mirga
Editor at Large
A federal district judge in Baltimore, Md., yesterday stayed the brand drug industry’s lawsuit challenging the December 2020 340B program administrative dispute resolution final rule.
Lawyers for Pharmaceutical Research and Manufacturers of America and U.S. Health and Human Services Secretary
… Tom Mirga
Editor at Large
Could ending the fights over limits on 340B contract pharmacy and encroachment on providers’ 340B savings hinge on hospitals accepting 340B reporting requirements? 340B Report Publisher and CEO Ted Slafsky raises that provocative question in his monthly column for Verity
… Tom Mirga
Editor at Large
More than 100 million Americans—almost one-third of the population, and many of them children—lack access to a usual source of primary care due to a shortage of providers in their community, leading to delays in care, poorer health outcomes, and
… Tom Mirga
Editor at Large
The chair of the New York Senate health committee has introduced legislation to repeal the April 1 shift of state Medicaid managed care pharmacy benefits to Medicaid fee for service. The state’s 340B health centers and Ryan White clinics say
… Laura Gilcrest
Editor at Large
National and state health center associations have filed amicus briefs in a lawsuit over California’s shift of Medicaid pharmacy benefits to Medicaid fee for service. They say the move will cost 340B providers in the state millions in savings needed
…
In the episode “340B Insights: The Current State of the 340B Program,” RxStrategies’ Jonathan Ghenn and Rhodie Smith connect with Ted Slafsky, Publisher and CEO of the 340B Report to share information on what’s important to Covered Entities and pharmacy professionals who manage a 340B Program and provide the best care to those they serve.
Laura Gilcrest
Editor at Large
Legislation in Indiana that would have required hospitals to file annual reports disclosing their median reimbursement for 340B-priced drugs, along with numerous other financial disclosures, has failed to advance and has no chance of passage this year.
The wide-ranging hospital
… Tom Mirga
Editor at Large
New research by drug industry contractor IQVIA questions whether claims identifiers can be used successfully to exclude 340B-purchased drugs from new Medicare drug inflation rebates or to protect manufacturers from paying both a new negotiated Medicare price and a 340B
…*Sign up for news summaries and alerts from 340B Report
